Table 1.
Patient characteristics.
| Age – median (IQR) | 74 (69–80) | |
| Body Surface Area – median (IQR) | 2.0 (1.85–2.0) | |
| Body Mass index – median (IQR) | 28 (24.4–31) | |
| Stage | T1-T4, N0 M0 | Low risk-6 |
| Intermediate risk-58 | ||
| High risk-103 | ||
| Node positive, M0 | 22 | |
| M1 | 52 | |
| Medical co-morbidity | Diabetes | 64 |
| Hypertension | 128 | |
| Ischemic heart disease | 71 | |
| Ethnicity | Afrocaribbean | 119 |
| Caucasian | 85 | |
| Asian | 40 | |
| Other | 6 | |
| ADT | LHRH agonist | 223 |
| Anti androgen | 7 | |
| CAB# | 20 | |
-Bicalutamide +Goserelin-14, Flutamide+Goserelin-3, Bicalutmaide +Leuprorelin-3.
#
CAB (Combined Androgen Blockade).